2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比

doi:10.3969/j.issn.1000-6621.2021.03.018

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (3): 295-298.doi: 10.3969/j.issn.1000-6621.2021.03.018

2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比

冯莹, 任斐()

710100 西安市胸科医院耐药结核科

收稿日期:2020-11-25 出版日期:2021-03-10 发布日期:2021-03-03
通信作者: 任斐 E-mail:doc.renfei@163.com
基金资助:
陕西省科技厅重点研发计划项目(2018SF-254)

Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)

FENG Ying, REN Fei()

Department of Drug-resistant Tuberculosis, Xi’an Chest Hospital, Shaanxi 710100, China

Received:2020-11-25 Online:2021-03-10 Published:2021-03-03
Contact: REN Fei E-mail:doc.renfei@163.com

摘要/Abstract

摘要：

介绍2019年南非《利福平耐药结核病管理临床指南》的要点,包括耐药结核病治疗方案的制订、药品选择、特殊人群的治疗、密切接触者的管理等,并与我国《耐药结核病化学治疗指南(2019年)》对比,对于不同之处进行分析。

关键词: 结核,抗多种药物性, 方案评价, 指南, 对比研究, 评论

Abstract:

To interpret the Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019),including how to choose drugs,formulate treatment regimens as well as how to treat special patients, manage close contacts; and then to compare this South Africa Guidelines with the Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019).

Key words: Tuberculosis,multidrug-resistant, Program evaluation, Guidelines, Comparative study, Comment

冯莹, 任斐. 2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比[J]. 中国防痨杂志, 2021, 43(3): 295-298. doi: 10.3969/j.issn.1000-6621.2021.03.018

FENG Ying, REN Fei. Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 295-298. doi: 10.3969/j.issn.1000-6621.2021.03.018

参考文献 14

[1]	Health Department of the Republic of South Africa. Management of Rifampicnresistant Tuberculosis: A Clinical Reference Guide. Pretoria: Health Department of the Republic of South Atrica, 2019.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
[3]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867. doi: 10.1056/NEJMoa1811867 URL pmid: 30865791
[4]	Balabanova Y, Fiebig L, Ignatyeva O, et al. Multidrug-resis-tant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax, 2017,72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. doi: 10.1136/thoraxjnl-2016-209841 URL pmid: 28209653
[5]	Barry PM, Lowenthal P, True L, et al. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med, 2017,196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. doi: 10.1164/rccm.201701-0013LE URL pmid: 28665681
[6]	World Health Organization. WHO consolidated guidelines on tuberculosis. Geneva: World Health Organization, 2020.
[7]	邓国防, 张培泽, 杨敏, 等. 二线注射剂治疗耐多药结核病的现状与思考. 中国防痨杂志, 2019,41(6):604-608. doi: 10.3969/j.issn.1000-6621.2019.06.004.
[8]	Liu Q, Sun F, Li Y, et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China. Clin Microbiol Infect, 2018,24(10):1035-1036. doi: 10.1016/j.cmi.2018.04.026. doi: 10.1016/j.cmi.2018.04.026 URL pmid: 29730223
[9]	Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet, 2019,394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3. doi: 10.1016/S0140-6736(19)31882-3 URL pmid: 31526739
[10]	Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med, 2018,15(7):e1002591. doi: 10.1371/journal.pmed.1002591. doi: 10.1371/journal.pmed.1002591 URL pmid: 29995958
[11]	Zhao Y, Fox T, Manning K, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retros-pective Cohort Study. Clin Infect Dis, 2019,68(9):1522-1529. doi: 10.1093/cid/ciy727. doi: 10.1093/cid/ciy727 URL pmid: 30165431
[12]	Collaborative Group for the Meta-Analysis of lndividual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. doi: 10.1016/S0140-6736(18)31644-1 URL pmid: 30215381
[13]	World Health Organization. Intent tuberculosis infection:Updated and consolidated guildes for programmatic management. Geneva: World Health Organization, 2019.
[14]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.

[1]	马艳, 高微微. 今非昔比:重视复治肺结核的合理施治[J]. 中国防痨杂志, 2021, 43(4): 313-317.
[2]	邓国防. 《结核病与糖尿病共病的治疗管理专家共识》解读[J]. 中国防痨杂志, 2021, 43(4): 318-321.
[3]	张晨晨, 谭卫国, 郭卉欣, 黄新春, 陈燕梅, 魏文静. 结核分枝杆菌感染对痰液菌群结构的影响[J]. 中国防痨杂志, 2021, 43(4): 357-363.
[4]	王佩, 赵国连, 雷倩, 郑丹, 崔晓利, 周俊. 荧光PCR探针熔解曲线法与微孔板法检测MTB耐药性的临床应用比较[J]. 中国防痨杂志, 2021, 43(2): 132-138.
[5]	费骏, 石仕元, 胡胜平, 胡德新, 张晨威. 经皮质骨轨迹螺钉在腰椎结核病椎间固定的生物力学研究[J]. 中国防痨杂志, 2021, 43(2): 171-177.
[6]	刘文峰, 周琳, 徐天亮, 易槐明, 王勇, 王谦信. 浙江省常山县“移动结核门诊”服务在结核病防控中的实施效果评价[J]. 中国防痨杂志, 2021, 43(1): 100-102.
[7]	王美杰, 李雨泽, 肖瑶, 吴明歧, 侯绍英. 糖尿病与糖尿病并发肺结核患者的血浆代谢组学对比研究[J]. 中国防痨杂志, 2021, 43(1): 36-41.
[8]	李潜, 汪林宝, 罗佩嘉, 韦林, 刘玉钢, 任磊鹏, 丁超. 两种技术对结核性脓胸不同手术标本病原学及耐药性检测结果分析[J]. 中国防痨杂志, 2021, 43(1): 52-57.
[9]	靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902.
[10]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[11]	周林, 刘二勇, 孟庆琳, 陈明亭, 周新华, 高微微, 林明贵, 谢汝明. 《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析[J]. 中国防痨杂志, 2020, 42(9): 910-915.
[12]	梁瑞云, 方伟军, 任会丽, 黎惠如, 张晖. 非结核分枝杆菌肺病并发与未并发糖尿病患者的CT征象研究[J]. 中国防痨杂志, 2020, 42(9): 962-967.
[13]	马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972.
[14]	张丽娟, 陶晓, 夏丽莉, 魏芬芬, 郑琦. 脊柱结核患者围手术期应用加速康复集束化护理临床路径表的价值[J]. 中国防痨杂志, 2020, 42(9): 981-986.
[15]	李爱芳, 崔晓利, 康磊, 雷静, 党丽云, 杨翰. 荧光PCR探针熔解曲线法检测结核分枝杆菌耐药性的价值[J]. 中国防痨杂志, 2020, 42(9): 998-1001.

2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比

Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 15

编辑推荐

Metrics

本文评价

友情链接